Skip to content

Comparative study of multimodal MRI and multiple transvaginal ultrasound techniques for dynamic evaluating tumor regression during the treatment of cervical cancer

Comparative study of multimodal MRI and multiple transvaginal ultrasound techniques for dynamic evaluating tumor regression during the treatment of cervical cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500097472
Enrollment
Unknown
Registered
2025-02-19
Start date
2023-02-06
Completion date
Unknown
Last updated
2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Interventions

Observation group:None

Sponsors

The 10th Hospital of Southern Medical University (Dongguan People's Hospital)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1) Cervical squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma confirmed by cervical biopsy pathology; 2) According to the standard clinical stage established by FIGO (International Association of Obstetrics and Gynecology) in 2009, it is FIGO IB-IV.A; Initial treatment with radiotherapy ± chemotherapy; 3) KPS score >=70 points; 4) No contraindications to radiotherapy, MRI and color ultrasound; 5) Subjects who voluntarily participate in this clinical study, who can provide or can find relevant examination reports.

Exclusion criteria

Exclusion criteria: (1) Subjects with tumors from other sites; (2) Those who cannot tolerate chemoradiotherapy or are allergic to MRI and ultrasound contrast media; (3) Those who are mentally abnormal and cannot cooperate with the examination.

Design outcomes

Primary

MeasureTime frame
Tumor size, extent of invasion;

Countries

China

Contacts

Public ContactChen Jialuo

The 10th Affiliated Hospital of Southern Medical University

374309326@qq.com+86 135 3287 8781

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026